Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Breast cancer, metastatic

4983 - Final analysis of the Male-GBG54 study: A prospective, randomised multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients


21 Oct 2018


Poster Discussion session - Breast cancer, metastatic


Cytotoxic Therapy;  Clinical Research

Tumour Site

Breast Cancer


Mattea Reinisch


M. Reinisch1, S. Seiler2, T. Hauzenberger3, S. Schmatloch4, H. Strittmatter5, D. Zahm6, C. Thode7, C. Jackisch8, D. Strik9, V. Moebus10, T. Reimer11, B. Sinn12, E. Stickeler13, F. Marme14, W. Janni15, A. Kamischke16, C. Rudlowski17, V. Nekljudova18, G. von Minckwitz19, S. Loibl19

Author affiliations

  • 1 Senologie/ Interdisziplinäres Brustzentrum, Kliniken Essen-Mitte, 45136 - Essen/DE
  • 2 Medicine And Research, German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE
  • 3 Frauenklinik, Klinikum St. Marien, Amberg/DE
  • 4 Brustzentrum, Elisabeth Krankenhaus, Kassel/DE
  • 5 Gynecology And Obstetrics, Rems-Murr-Hospital GmbH, Winnenden/DE
  • 6 Brustzentrum, SRH Wald-Klinikum, Gera/DE
  • 7 Medizinische Mikrobiologie Und Immunologie, amedes MVZ Wagnerstibbe für Laboratoriumsmedizin, Göttingen/DE
  • 8 Gynäkologie Und Geburtshilfe, Klinikum Offenbach GmbH, 63069 - Offenbach/DE
  • 9 Frauenheilkunde Und Geburtshilfe, Endokrinologikum, Berlin/DE
  • 10 Department Of Gynecology And Obstetrics, Klinikum Frankfurt Höchst, Academic Hospital of the Goethe University Frankfurt, Frankfurt/DE
  • 11 Klinikum Südstadt, University of Rostock, 18059 - Rostock/DE
  • 12 Pathologie, Charité-Universitätsmedizin, Berlin/DE
  • 13 Gynäkologie Und Geburtsmedizin, Uniklinik RWTH, Aachen/DE
  • 14 Gynecologic Oncology, Nationales Zentrum für Tumorerkrankungen (NCT), 69120 - Heidelberg/DE
  • 15 Frauenheilkunde Und Geburtshilfe, Universitätsklinikum, Ulm/DE
  • 16 Frauenheilkunde Und Geburtshilfe, MVZ Kinderwunsch und Hormonzentrum, Münster/DE
  • 17 Gynäkologie, Evangelisches Krankenhaus, Bergisch Gladbach/DE
  • 18 Statistics, German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE
  • 19 Department Of Medicine And Research, German Breast Group (GBG) Forschungs GmbH, 63263 - Neu-Isenburg/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4983


Over 90% of mBC pts have hormone receptor positive disease. Until today tam is considered the standard of care. Due to the low incidence of mBC, there is a lack of data regarding its efficacy and safety. No prospectively randomized study in mBC pts has been completed so far. The Male-GBG54 study is the first prospective, randomized, multicenter trial evaluating the efficacy and safety of different endocrine treatment options in male pts with BC.


In the Male-GBG54 trial (NCT01638247), pts were randomized to receive tam 20mg/day per os (p.o.) in Arm A, tam + GnRHa subcutaneous (s.c.) q3m in Arm B and exemestane 25 mg/day p.o. + GnRHa s.c. in Arm C for 6 months (mo) as (neo)adjuvant or metastatic therapy. Further treatment was conducted as per local guidelines. Primary objective was the estradiol (E2) suppression after 3 mo. Secondary objectives were the E2 suppression after 6 mo and levels of different steroidal hormones after 3 and 6 mo. Quality of life was assessed using validated questionnaires. 14 pts/group were needed for the F-test to have 80% power to detect a difference in estradiol decrease between the groups at the 5% significance level.


Between October 2012 and May 2017, 55 pts were randomized in Germany, of whom 46 pts were fully evaluable and comprised the 6-mo analysis set. The median age was 62 years. Baseline characteristics were well balanced between the 3 arms. The median E2 level with tam increased by 67% after 3 mo and by 41% after 6 mo. In pts receiving tam + GnRH and AI+ GnRH, there was an initial decrease of E2 after 3 mo of 85% and 73% respectively. After 6 mo of therapy the decrease was 59% and 63% respectively. Other hormone parameters will also be presented at the meeting.


This is worldwide the first fully recruited prospective randomized trial, evaluating the impact of 3 different endocrine treatments in male BC. The analysis revealed an increase of E2 levels along the course of therapy after an initial steep decrease when GnRHa was given. The therapy was well tolerated with no safety signals.

Clinical trial identification

Male-GBG54 trial (NCT01638247)

Editorial Acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.